Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM

Post-prandial amylin concentrations are increased by sulphonylurea, but unchanged by basal insulin, in NIDDM

Bibliographic Details
Main Authors:	Rachman, J, Payne, M, Levy, J, Barrow, B, Manley, SE, Holman, R, Turner, R
Format:	Journal article
Published:	1996

Similar Items

Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
by: Rachman, J, et al.
Published: (1998)

Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy.
by: Rachman, J, et al.
Published: (1997)

A practical guide to basal and prandial insulin therapy.
by: Holman, R, et al.
Published: (1985)

Sulphonylurea failure in type 2 diabetes: treatment with a basal insulin supplement.
by: Holman, R, et al.
Published: (1987)

RESTING THE BETA-CELLS WITH INSULIN IN NIDDM DOES NOT IMPROVE BETA-CELL FUNCTION NOR PROINSULIN PROCESSING
by: Rachman, J, et al.
Published: (1995)

Insulin use in NIDDM. Rationale based on pathophysiology of disease.
by: Turner, R, et al.
Published: (1990)

Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes.
by: Holman, R, et al.
Published: (2007)

Normalization of insulin responses to glucose by overnight infusion of glucagon-like peptide 1 (7-36) amide in patients with NIDDM.
by: Rachman, J, et al.
Published: (1996)

Near-normalisation of diurnal glucose concentrations by continuous administration of glucagon-like peptide-1 (GLP-1) in subjects with NIDDM.
by: Rachman, J, et al.
Published: (1997)

Pathogenesis of NIDDM--a disease of deficient insulin secretion.
by: Turner, R, et al.
Published: (1988)

Differences in insulin treatment satisfaction following randomized addition of biphasic, prandial or basal insulin to oral therapy in type 2 diabetes.
by: Farmer, A, et al.
Published: (2011)

No glycemic benefit from guar administration in NIDDM.
by: Holman, R, et al.
Published: (1987)

Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
by: Holman, R, et al.
Published: (1991)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
by: Ivan Ivanovich Dedov, et al.
Published: (2014-12-01)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years
by: Matthews, DR, et al.
Published: (1998)

CIGMA as a tool in the study of NIDDM.
by: Turner, R, et al.
Published: (1988)

Treatment of NIDDM - Progressive requirement for polypharmacy to attain glycaemic goals
by: Cull, C, et al.
Published: (1997)

Familial association and lambda s for diabetes, obesity, high triglycerides and low HDL-cholesterol in sibs of NIDDM patients
by: Levy, J, et al.
Published: (1997)

Familial association and lambda s for diabetes, obesity, high triglycerides and low HDL-cholesterol in sibs of NIDDM patients.
by: Levy, J, et al.
Published: (1997)

Segregation analysis of NIDDM in Caucasian families.
by: Cook, J, et al.
Published: (1994)

GLP-1 and exendin-4 increase post-prandial leptin in type 2 diabetes
by: Stoeckli, R, et al.
Published: (2005)

Effects of ethnicity on metabolic control during the first six years of NIDDM
by: Davis, T, et al.
Published: (1997)

UKPDS 18: Estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy
by: Eeley, E, et al.
Published: (1996)

Subcutaneous exendin-4 lowers both post-prandial and fasting plasma glucose in Type 2 diabetes
by: Maksoud, H, et al.
Published: (2000)

The first and only combination of basal and prandial insulin analogs degludec and aspart: the position of Russian endocrinologists
by: M. V. Shestakova, et al.
Published: (2021-07-01)

Efficacy over six years of sulphonylurea plus insulin therapy in type 2 diabetic patients in the UKPDS
by: Cull, C, et al.
Published: (2000)

Coronary heart disease and risk factors in NIDDM--experience from the United Kingdom Prospective Diabetes Study.
by: Turner, R, et al.
Published: (1997)

UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group.
by: Matthews, DR, et al.
Published: (1998)

Sulphonylureas and hypoglycaemia.
by: Ferner, R, et al.
Published: (1988)

Glycaemic improvement over one year in a double-blind trial of acarbose in 1,946 NIDDM patients
by: Holman, R, et al.
Published: (1996)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
by: Turner, R, et al.
Published: (1998)

UKPDS 18: estimated dietary intake in type 2 diabetic patients randomly allocated to diet, sulphonylurea or insulin therapy. UK Prospective Diabetes Study Group.
by: Eeley, E, et al.
Published: (1996)

Risk factors predicting progression of diabetic retinopathy over six years in 1579 NIDDM patients
by: Stratton, I, et al.
Published: (1996)

Maintenance of basal plasma glucose and insulin concentrations in maturity-onset diabetes.
by: Holman, R, et al.
Published: (1979)

Amylin in the Periphery
by: Peter J. Wookey, et al.
Published: (2003-01-01)

Specific insulin and proinsulin in normal glucose tolerant first-degree relatives of NIDDM patients
by: R. Coifman, et al.
Published: (1999-01-01)

Sulphonylurea therapy over six years does not delay progression to diabetes
by: Herlihy, O, et al.
Published: (2000)

Permanent neonatal diabetes: combining sulphonylureas with insulin may be an effective treatment
by: Misra, S, et al.
Published: (2018)

The effect of glibenclamide on insulin secretion at normal glucose concentrations
by: Riefflin, A, et al.
Published: (2014)

The effect of glibenclamide on insulin secretion at normal glucose concentrations.
by: Riefflin, A, et al.
Published: (2015)